Core Viewpoint - The company, Fuhong Hanlin, has received acceptance for its New Drug Application (NDA) for the innovative anti-PD-1 monoclonal antibody, Hanshuozhuang (Slulizumab), for use in combination with platinum-based chemotherapy in the neoadjuvant and postoperative adjuvant treatment of PD-L1 positive, resectable gastric cancer patients, which has been prioritized for review by the National Medical Products Administration (NMPA) [1][2] Group 1 - The acceptance of the NDA and its inclusion in the priority review process will significantly shorten the review timeline to 130 working days, accelerating the market entry of Hanshuozhuang for perioperative treatment of gastric cancer [1] - Gastric cancer is a highly prevalent malignancy globally, with high incidence and mortality rates, and there is an urgent clinical need for effective therapies in the perioperative setting, as no immunotherapy has been approved in China for this phase [1] Group 2 - The NDA is primarily based on the positive results from the key study ASTRUM-006, which showed that Hanshuozhuang combined with chemotherapy significantly improved event-free survival (EFS) and pathological complete response (pCR) rates compared to the control group, with a notable reduction in recurrence risk and manageable overall safety [2] - Hanshuozhuang, as a core anti-tumor drug for the company, demonstrates unique advantages in treating various solid tumors due to its differentiated mechanism, which enhances T cell activation and preserves CD28 signaling [2] - Currently, Hanshuozhuang has been approved for multiple indications, including squamous non-small cell lung cancer, and is available in over 40 countries, covering nearly half of the global population [2]

Core Viewpoint - The rapid market entry of H drug (Hanshuanzhuang) in India marks a significant milestone for the company, being the first PD-1 inhibitor approved for first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) in the country, enhancing treatment options for local patients [1][2]. Group 1: Product Approval and Market Entry - H drug received approval from the Central Drugs Standard Control Organization (CDSCO) in India at the end of June 2025 and completed its first shipment to the Indian market within 30 days [1][2]. - The drug is the first and only PD-1 monoclonal antibody approved for ES-SCLC in India, addressing a critical unmet clinical need in the treatment landscape [2]. Group 2: Market Context and Demand - In 2022, India reported over 81,000 new lung cancer cases and more than 75,000 deaths, with lung cancer being a leading cause of cancer incidence and mortality in the region [2]. - The approval and commercialization of H drug provide an innovative immunotherapy option for patients suffering from extensive-stage small cell lung cancer [2]. Group 3: Strategic Partnerships - The company has partnered with Intas, a leading local pharmaceutical firm, to facilitate the commercialization of H drug in India, leveraging Intas's extensive market insights and sales network [2][3]. Group 4: Global Operations and Supply Chain - The successful shipment of H drug to India demonstrates the company's efficient global supply chain operations and its commitment to bringing innovative Chinese-origin drugs to international markets [4]. - The company has established an integrated biopharmaceutical platform since its inception in 2010, with capabilities spanning research, production, and commercial operations, ensuring compliance with international standards [4]. Group 5: Financial Performance - The company reported a revenue of 5.724 billion yuan in 2024, reflecting a year-on-year growth of 6.1%, with global sales of H drug increasing by 17.2% [5]. - Analysts anticipate that the ongoing international promotion of H drug will further enhance the company's overseas revenue share, positioning it as a core growth driver for the future [5].

Core Viewpoint - The company has successfully delivered the first batch of its self-developed anti-PD-1 monoclonal antibody, H drug (brand name: Hanshuang, international name: Hetronifly), to the Indian market, marking a significant milestone in its product rollout [1] Group 1 - The H drug received approval from the Central Drugs Standard Control Organization (CDSCO) in India in June 2025 for first-line treatment of extensive-stage small cell lung cancer [1] - This approval makes the H drug the first anti-PD-1 monoclonal antibody to be approved for this indication in India [1]

Core Viewpoint - Fosun Pharma's subsidiary, Fuhong Hanlin, has successfully delivered the first batch of its self-developed anti-PD-1 monoclonal antibody, H drug, to the Indian market, marking its entry into the world's most populous country and addressing urgent clinical needs in small cell lung cancer (SCLC) [1] Company Summary - Fuhong Hanlin's H drug, also known as Hanshuang and Sru Li monoclonal antibody, is the first anti-PD-1 monoclonal antibody approved for first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) globally [1] - The drug has received approval for marketing in nearly 40 countries and regions, including China, the UK, Germany, India, Indonesia, and Singapore, covering nearly half of the global population [1]